ZED1227

About Zedira

Zedira GmbH is a German biotech firm founded in 2006, pioneering the clinical validation of transglutaminases as therapeutic targets. The company's core asset is ZED1227, a first-in-class oral TG2 inhibitor that successfully completed a Phase 2a study in celiac disease and is advancing in further trials, including for non-alcoholic fatty liver disease (NAFLD). Beyond its therapeutic pipeline, Zedira is a global supplier of high-quality transglutaminase-related research reagents, serving both academia and industry, and has established key partnerships with Dr. Falk Pharma and Takeda for clinical development.

About Zedira

Zedira GmbH is a German biotech firm founded in 2006, pioneering the clinical validation of transglutaminases as therapeutic targets. The company's core asset is ZED1227, a first-in-class oral TG2 inhibitor that successfully completed a Phase 2a study in celiac disease and is advancing in further trials, including for non-alcoholic fatty liver disease (NAFLD). Beyond its therapeutic pipeline, Zedira is a global supplier of high-quality transglutaminase-related research reagents, serving both academia and industry, and has established key partnerships with Dr. Falk Pharma and Takeda for clinical development.

Therapeutic Areas

Other Celiac Disease Drugs